Combination chemotherapy only for stage II non-Hodgkin's lymphoma
| Autor: | Ezzeldin M. Ibrahim, Abdelaziz Al-Qourain, Hussien Al-Freihi, Ali Abdel Satir, Gamel H. Abssod, M. B. Satti, Suleiman A. Al-Mohaya, Hassan Y. Al-Idrissi |
|---|---|
| Rok vydání: | 1986 |
| Předmět: |
Adult
medicine.medical_specialty Vincristine Cyclophosphamide Adolescent Lymphoma Bleomycin Gastroenterology chemistry.chemical_compound Prednisone Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged Neoplasm Staging Leukopenia business.industry Combination chemotherapy Middle Aged medicine.disease Non-Hodgkin's lymphoma Surgery Oncology chemistry Doxorubicin medicine.symptom business medicine.drug |
| Zdroj: | European journal of cancerclinical oncology. 22(2) |
| ISSN: | 0277-5379 |
| Popis: | Twenty-six previously untreated patients with clinical stage (CS) II B non-Hodgkin's lymphoma (NHL) were treated with systemic chemotherapy only. Patients received bleomycin, adriamycin, cyclophosphamide, vincristine and prednisone (BACOP). All patients had intermediate- or high-grade lymphoma. Objective response was demonstrated in 25 patients (96%), with 21 patients (81%) achieving complete remission (CR). Two of CR patients developed unsalvageable relapse, the remaining 19 patients are still alive and disease-free. The median duration of CR has not been reached. Of four patients (15%) with documented partial remission (PR), three were salvaged using second-line therapy. Over a median follow-up of 12 months (range, 3-30), 22 patients (85%) are alive and disease-free, of whom 16 (62%) have survived more than 1 yr. Bulky disease or gastrointestinal tract (GIT) involvement did not influence the CR rate. Our results compared favorably with radiation therapy for stage II NHL; however, a larger controlled and randomized study is warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|